Eli Lilly reported second-quarter earnings and revenue that exceeded expectations, driven by strong sales of its weight loss drug Zepbound and diabetes treatment Mounjaro. The company raised its 2026 revenue forecast to $85-$87 billion from $82-$85 billion, reflecting continued growth despite lower drug prices in the U.S. New obesity pill Foundayo contributed $98 million in sales in its first quarter. Lilly's global prescription volumes surged, supported by expanding Medicare coverage for obesity drugs, positioning the company for further growth in the coming years.
Eli Lilly will present mid-stage trial results for eloraTZP, a two-drug obesity treatment, on September 30. The data will show if the combo offers significantly better weight loss and tolerability than tirzepatide alone, crucial for sustaining the co...
The FDA has granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with estrogen receptor-positive (ER+), HER2-negative, ESR1-mutated advanced or metastatic breast cancer after progressio...
